Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2015

View Archived Issues

Phylogica's 1746-Omomyc fusion reduces tumor size in mouse model of breast cancer

Celyad provides update on C-Cure in Europe

Lundbeck reviews key events of third quarter 2015

Celgene offers pipeline update for third quarter 2015

Investigators present first-in-human results of JF-04 stent for coronary lesions

Squamous NSCLC response rate improved when necitumumab added to paclitaxel-carboplatin

RedHill Biopharma and IntelGenx confirm first European approval of Rizaport

FDA grants breakthrough therapy designation to SD-809 for tardive dyskinesia

Kite Pharma begins phase II trial of KTE-C19 mantle cell lymphoma

PhaseBio begins phase IIa study of once-weekly basal insulin, PE0-139

Caldan Therapeutics finances development of antidiabetic free fatty acid receptor modulators

FDA grants tentative approval to Xtampza for chronic pain

Pivotal phase III trial of RSV-F vaccine in older adults gets started by Novamax

Astellas to establish presence in ophthalmology through acquisition of Ocata Therapeutics

Pfizer reports development of dopamine D1 receptor ligands

Novartis discloses PI3K-gamma inhibitors

Idenix Pharmaceuticals divulges anti-HCV nucleosides

Gruenenthal patents Cav2.2 blockers

AbbVie presents CSF-1R inhibitors

Na-GST-1/Alhydrogel hookworm vaccine well tolerated and immunogenic in phase I studies

Nerviano Medical Sciences characterizes JAK-2 inhibitor NMS-P113

Biosimilar etanercept achieves endpoints in phase III psoriasis study

Fera Pharmaceuticals licenses U.S. rights to NicOx's naproxcinod

Janssen licenses rights to Hanmi's oxyntomodulin-based therapies

New genetic factors linked to persistent ADHD

ATR inhibitor VX-970 in advanced cancer

Proteome Sciences reports data on CK1d inhibitors for Alzheimer's disease

PZ-128 shows clinical promise

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...